New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies

New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies

Mar 21, 2013
Source URL: https://qa1.novartis.us/us-en/news/media-releases/new-analysis-shows-novartis-drug-gilenya-significantly-reduced-rate-brain-volume-loss-across-three-large-phase-iii-studies-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/new-analysis-shows-novartis-drug-gilenya-significantly-reduced-rate-brain-volume-loss-across-three-large-phase-iii-studies-0